Trial Profile
A Randomized, Sponsor-Open, Investigator-Blinded, Subject-Blinded, Placebo-Controlled, Single-Ascending Dose (SAD) and Multiple-Ascending Dose (MAD) Study to Investigate the Safety, Tolerability, and Pharmacokinetics of RO7049389 in Healthy Chinese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Feb 2021
Price :
$35
*
At a glance
- Drugs Linvencorvir (Primary)
- Indications Hepatitis B
- Focus Adverse reactions
- Sponsors Roche
- 01 Feb 2021 Results of Population Pharmacokinetic Modeling Incorporating Active Hepatic Uptake Supports from three trials (NCT02952924, NCT03570658 and NCT03717064) published in the Clinical Pharmacology and Therapeutics
- 31 May 2019 Status changed from recruiting to completed.
- 04 Feb 2019 Planned End Date changed from 16 Jan 2019 to 1 May 2019.